{
  "kind": "treatment",
  "slug": "galantamine-razadyne",
  "type": "cognitive-enhancer",
  "name": "Galantamine (Razadyne)",
  "summary": "A cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease.",
  "description": "Galantamine is a reversible, competitive acetylcholinesterase inhibitor and nicotinic receptor modulator used to improve cognitive function in patients with mild to moderate Alzheimer's disease. It increases the concentration of acetylcholine in the synaptic cleft, thereby enhancing cholinergic neurotransmission. It may modestly improve cognition, function, and behavior, but it does not alter disease progression.",
  "category": "medications/cognitive-enhancers",
  "tags": [
    "alzheimer's disease",
    "cholinesterase inhibitor",
    "cognitive enhancer"
  ],
  "metadata": {
    "drug_classes": [
      "Cholinesterase Inhibitor",
      "Cognitive Enhancer"
    ],
    "therapeutic_categories": [
      "Alzheimer's Disease",
      "Dementia"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Razadyne"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "B",
    "age_groups": [
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Neurology",
      "Geriatrics",
      "Psychiatry"
    ],
    "fda_approval_year": 2001
  },
  "clinical_metadata": {
    "primary_indications": [
      "Dementia"
    ],
    "off_label_uses": [
      "Mild cognitive impairment (limited evidence)",
      "Vascular dementia (limited evidence)"
    ],
    "contraindications": [
      "Severe hepatic impairment",
      "Severe renal impairment",
      "Known hypersensitivity to galantamine"
    ],
    "monitoring_required": [
      "Heart rate (risk of bradycardia)",
      "Weight and appetite",
      "GI tolerance"
    ],
    "efficacy_rating": {
      "cognition": 3,
      "function": 3,
      "behavior": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "galantamine",
      "razadyne",
      "cholinesterase inhibitor",
      "alzheimer's medication"
    ],
    "synonyms": [
      "galantamine hydrobromide",
      "Reminyl"
    ],
    "common_misspellings": [
      "galantine",
      "galanthamine"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Mild Alzheimer's disease",
        "Moderate Alzheimer's disease"
      ]
    },
    {
      "type": "mechanism",
      "text": "Inhibits acetylcholinesterase and modulates nicotinic receptors to enhance cholinergic neurotransmission in the brain."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "4 mg twice daily",
        "titrate": "Increase to 8 mg twice daily after at least 4 weeks if tolerated",
        "max": "12 mg twice daily"
      },
      "geriatric": "Same as adult, but titrate more slowly if needed",
      "hepatic_impairment": "Moderate: maximum 16 mg/day; Severe: contraindicated",
      "renal_impairment": "Moderate: maximum 16 mg/day; Severe: contraindicated"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Immediate-release tablets: 4 mg, 8 mg, 12 mg",
        "Extended-release capsules: 8 mg, 16 mg, 24 mg",
        "Oral solution: 4 mg/mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Clinical improvement may be seen within weeks; benefits maintained with continued treatment."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "vomiting",
        "diarrhea",
        "loss of appetite",
        "dizziness",
        "headache"
      ],
      "less_common": [
        "bradycardia",
        "syncope",
        "weight loss"
      ],
      "serious": [
        "severe bradyarrhythmia",
        "GI bleeding",
        "seizures"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Use caution in patients with cardiac conduction disorders",
        "May increase gastric acid secretionâ€”caution in ulcer disease"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Other cholinergic drugs",
          "risk": "Additive cholinergic effects",
          "action": "Avoid combination"
        },
        {
          "with": "Anticholinergic drugs",
          "risk": "Reduced efficacy",
          "action": "Avoid if possible"
        },
        {
          "with": "Beta-blockers",
          "risk": "Increased bradycardia",
          "action": "Monitor heart rate"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Heart rate and blood pressure",
        "Weight",
        "GI side effects"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "No adequate studies; use only if clearly needed",
      "lactation": "Unknown if excreted in breast milk; avoid use",
      "pediatrics": "Not indicated",
      "geriatrics": "Monitor for bradycardia, weight loss, and dehydration"
    },
    {
      "type": "tapering",
      "text": "May be discontinued abruptly if needed, but gradual taper recommended to monitor for return of symptoms."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Therapeutic benefit may be modest; consider discontinuation if no improvement after several months",
        "Ensure adequate fluid intake to reduce GI side effects"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Razadyne Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Alzheimer's Association Treatment Overview",
          "url": "https://www.alz.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Galantamine (Razadyne): Alzheimer's Medication Guide",
    "description": "Galantamine (Razadyne) is a cholinesterase inhibitor for mild to moderate Alzheimer's disease. Learn dosing, side effects, and precautions."
  }
}
